{"doc_id": "32445440", "type of study": "Therapy", "title": "", "abstract": "Remdesivir for the Treatment of Covid-19 - Final Report.\nAlthough several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious.\nWe conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.\nPatients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days.\nThe primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only.\nA total of 1062 patients underwent randomization (with 541 assigned to remdesivir and 521 to placebo).\nThose who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; P<0.001, by a log-rank test).\nIn an analysis that used a proportional-odds model with an eight-category ordinal scale, the patients who received remdesivir were found to be more likely than those who received placebo to have clinical improvement at day 15 (odds ratio, 1.5; 95% CI, 1.2 to 1.9, after adjustment for actual disease severity).\nThe Kaplan-Meier estimates of mortality were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03).\nSerious adverse events were reported in 131 of the 532 patients who received remdesivir (24.6%) and in 163 of the 516 patients who received placebo (31.6%).\nOur data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.\n(Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705.).\nCopyright \u00a9 2020 Massachusetts Medical Society.\n", "Evidence Map": {"Enrollment": [{"term": "Covid-19-Final Report", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 53}, {"term": "adults", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 103}, {"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 113, "end": 125}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 131, "end": 139}, {"term": "lower respiratory", "negation": "affirmed", "UMLS": {}, "start": 160, "end": 177}, {"term": "adults", "negation": "affirmed", "UMLS": {}, "start": 92, "end": 98}, {"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 108, "end": 120}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 126, "end": 134}, {"term": "lower respiratory tract infection", "negation": "affirmed", "UMLS": {}, "start": 155, "end": 188}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Remdesivir for the Treatment of Covid-19-Final Report .", "Evidence Elements": {"Participant": [{"term": "Covid-19-Final Report", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 53}], "Intervention": [{"term": "Remdesivir", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 10, "has_chemical": [{"text": "remdesivir", "maps_to": "C4726677:remdesivir", "start": 0, "end": 10}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 ( Covid-19 ) , no antiviral agents have yet been shown to be efficacious .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "We conducted a double-blind , randomized , placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection .", "Evidence Elements": {"Participant": [{"term": "adults", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 103}, {"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 113, "end": 125}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 131, "end": 139}, {"term": "lower respiratory", "negation": "affirmed", "UMLS": {}, "start": 160, "end": 177}], "Intervention": [{"term": "intravenous remdesivir", "negation": "affirmed", "UMLS": {}, "start": 71, "end": 93, "has_chemical": [{"text": "remdesivir", "maps_to": "C4726677:remdesivir", "start": 12, "end": 22, "has_route": ["intravenous"]}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Patients were randomly assigned to receive either remdesivir ( 200 mg loading dose on day 1 , followed by 100 mg daily for up to 9 additional days ) or placebo for up to 10 days .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "remdesivir", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 60, "has_chemical": [{"text": "remdesivir", "maps_to": "C4726677:remdesivir", "start": 0, "end": 10}], "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 152, "end": 159, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary outcome was the time to recovery , defined by either discharge from the hospital or hospitalization for infection-control purposes only .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "time to recovery", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 44}, {"term": "discharge from the hospital", "negation": "affirmed", "UMLS": {}, "start": 65, "end": 92}, {"term": "hospitalization", "negation": "affirmed", "UMLS": {}, "start": 96, "end": 111}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "A total of 1062 patients underwent randomization ( with 541 assigned to remdesivir and 521 to placebo ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "remdesivir", "negation": "affirmed", "UMLS": {}, "start": 72, "end": 82, "has_chemical": [{"text": "remdesivir", "maps_to": "C4726677:remdesivir", "start": 0, "end": 10}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Those who received remdesivir had a median recovery time of 10 days ( 95 % confidence interval [ CI ] , 9 to 11 ) , as compared with 15 days ( 95 % CI , 13 to 18 ) among those who received placebo ( rate ratio for recovery , 1.29 ; 95 % CI , 1.12 to 1.49 ; P < 0.001 , by a log-rank test ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "remdesivir", "negation": "affirmed", "UMLS": {}, "start": 19, "end": 29, "has_chemical": [{"text": "remdesivir", "maps_to": "C4726677:remdesivir", "start": 0, "end": 10}], "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 189, "end": 196, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "median recovery time", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 56}, {"term": "rate ratio for", "negation": "affirmed", "UMLS": {}, "start": 199, "end": 213}], "Observation": [{"term": "10 days", "negation": "affirmed", "UMLS": {}, "start": 60, "end": 67}, {"term": "15 days", "negation": "affirmed", "UMLS": {}, "start": 133, "end": 140}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "remdesivir", "has_chemical": [{"text": "remdesivir", "maps_to": "C4726677:remdesivir", "start": 0, "end": 10}], "has_relation": "N/A"}, "Observation": "10 days", "Outcome": "median recovery time", "Count": ""}, {"Intervention": {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "15 days", "Outcome": "median recovery time", "Count": ""}]}, {"Section": "RESULTS", "Text": "In an analysis that used a proportional-odds model with an eight-category ordinal scale , the patients who received remdesivir were found to be more likely than those who received placebo to have clinical improvement at day 15 ( odds ratio , 1.5 ; 95 % CI , 1.2 to 1.9 , after adjustment for actual disease severity ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "remdesivir", "negation": "affirmed", "UMLS": {}, "start": 116, "end": 126, "has_chemical": [{"text": "remdesivir", "maps_to": "C4726677:remdesivir", "start": 0, "end": 10}], "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 180, "end": 187, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "clinical improvement", "negation": "affirmed", "UMLS": {}, "start": 196, "end": 216}], "Observation": [{"term": "more likely", "negation": "affirmed", "UMLS": {}, "start": 144, "end": 155}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "remdesivir", "has_chemical": [{"text": "remdesivir", "maps_to": "C4726677:remdesivir", "start": 0, "end": 10}], "has_relation": "N/A"}, {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Observation": "more likely", "Outcome": "clinical improvement", "Count": ""}]}, {"Section": "RESULTS", "Text": "The Kaplan-Meier estimates of mortality were 6.7 % with remdesivir and 11.9 % with placebo by day 15 and 11.4 % with remdesivir and 15.2 % with placebo by day 29 ( hazard ratio , 0.73 ; 95 % CI , 0.52 to 1.03 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "remdesivir", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 66, "has_chemical": [{"text": "remdesivir", "maps_to": "C4726677:remdesivir", "start": 0, "end": 10}], "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 83, "end": 90, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "remdesivir", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 66, "has_chemical": [{"text": "remdesivir", "maps_to": "C4726677:remdesivir", "start": 0, "end": 10}], "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 83, "end": 90, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "Kaplan-Meier estimates of mortality", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 39}], "Observation": [{"term": "6.7 %", "negation": "affirmed", "UMLS": {}, "start": 45, "end": 50}, {"term": "11.9 %", "negation": "affirmed", "UMLS": {}, "start": 71, "end": 77}, {"term": "11.4 %", "negation": "affirmed", "UMLS": {}, "start": 105, "end": 111}, {"term": "15.2 %", "negation": "affirmed", "UMLS": {}, "start": 132, "end": 138}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "remdesivir", "has_chemical": [{"text": "remdesivir", "maps_to": "C4726677:remdesivir", "start": 0, "end": 10}], "has_relation": "N/A"}, "Observation": "6.7 %", "Outcome": "Kaplan-Meier estimates of mortality", "Count": ""}, {"Intervention": {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "11.9 %", "Outcome": "Kaplan-Meier estimates of mortality", "Count": ""}, {"Intervention": {"term": "remdesivir", "has_chemical": [{"text": "remdesivir", "maps_to": "C4726677:remdesivir", "start": 0, "end": 10}], "has_relation": "N/A"}, "Observation": "11.4 %", "Outcome": "Kaplan-Meier estimates of mortality", "Count": ""}, {"Intervention": {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "15.2 %", "Outcome": "Kaplan-Meier estimates of mortality", "Count": ""}]}, {"Section": "RESULTS", "Text": "Serious adverse events were reported in 131 of the 532 patients who received remdesivir ( 24.6 % ) and in 163 of the 516 patients who received placebo ( 31.6 % ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "remdesivir", "negation": "affirmed", "UMLS": {}, "start": 77, "end": 87, "has_chemical": [{"text": "remdesivir", "maps_to": "C4726677:remdesivir", "start": 0, "end": 10}], "has_relation": "N/A"}], "Outcome": [{"term": "Serious adverse events", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 22}], "Observation": [], "Count": [{"term": "131 of the 532 patients", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 63}, {"term": "24.6 %", "negation": "affirmed", "UMLS": {}, "start": 90, "end": 96}, {"term": "163 of the 516 patients", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 129}]}, "Evidence Propositions": [{"Intervention": {"term": "remdesivir", "has_chemical": [{"text": "remdesivir", "maps_to": "C4726677:remdesivir", "start": 0, "end": 10}], "has_relation": "N/A"}, "Observation": "", "Count": "131 of the 532 patients", "Outcome": "Serious adverse events"}, {"Intervention": {"term": "remdesivir", "has_chemical": [{"text": "remdesivir", "maps_to": "C4726677:remdesivir", "start": 0, "end": 10}], "has_relation": "N/A"}, "Observation": "", "Count": "24.6 %", "Outcome": "Serious adverse events"}]}, {"Section": "CONCLUSIONS", "Text": "Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection .", "Evidence Elements": {"Participant": [{"term": "adults", "negation": "affirmed", "UMLS": {}, "start": 92, "end": 98}, {"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 108, "end": 120}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 126, "end": 134}, {"term": "lower respiratory tract infection", "negation": "affirmed", "UMLS": {}, "start": 155, "end": 188}], "Intervention": [{"term": "remdesivir", "negation": "affirmed", "UMLS": {}, "start": 19, "end": 29, "has_chemical": [{"text": "remdesivir", "maps_to": "C4726677:remdesivir", "start": 0, "end": 10}], "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 46, "end": 53, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "time to recovery", "negation": "affirmed", "UMLS": {}, "start": 72, "end": 88}], "Observation": [{"term": "superior", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 42}, {"term": "shortening", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 67}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "remdesivir", "has_chemical": [{"text": "remdesivir", "maps_to": "C4726677:remdesivir", "start": 0, "end": 10}], "has_relation": "N/A"}, "Observation": "shortening", "Outcome": "time to recovery", "Count": ""}, {"Intervention": {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "shortening", "Outcome": "time to recovery", "Count": ""}]}, {"Section": "CONCLUSIONS", "Text": "( Funded by the National Institute of Allergy and Infectious Diseases and others ; ACTT-1 ClinicalTrials.gov number , NCT04280705 . ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 Massachusetts Medical Society .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}